Form 4: Amgen Director Amy E. Miles Receives Stock Grant

Amgen Inc. director Amy E. Miles acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Summary

• Director Amy E. Miles was granted 665 Restricted Stock Units (RSUs) on May 19, 2026.
• The RSUs vested immediately under the Amgen Inc. 2009 Director Incentive Program.
• Following this transaction, the director's total beneficial ownership increased to 5,640 shares of common stock.
• The transaction was settled on a one-to-one basis for common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company operations or financial strategy.

Positives

• Increased equity alignment between the director and shareholders.
• Standard compensation practice for board members under the established 2009 Equity Incentive Plan.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine director compensation disclosure.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation within the biotechnology sector, reflecting standard corporate governance practices for board member equity retention.

Comparison to Industry Standards

• The grant of RSUs to directors is a standard practice among large-cap pharmaceutical and biotechnology companies to align board interests with long-term shareholder value.
• The use of a 2009 Equity Incentive Plan is consistent with long-standing governance structures for mature S&P 500 companies.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• None.

Key Dates

Keywords

Amgen, AMGN, Form 4, Director Compensation, Insider Transaction, Equity Incentive Plan